A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Women with Early Stage Breast Cancer
To find out if duloxetine (cymbalta) decreases joint pain in women with aromatase inhibitor-associated musculoskeletal syndrome (AIMSS).
Aromatase inhibitor-associated musculoskeletal syndrome (AIMSS).
1. Post-menopausal female with estrogen receptor (ER) and/or progesterone receptor (PgR) positive breast cancer with no evidence of metastatic disease
2. Must have recovered completely from either mastectomy or breast sparing surgery
3. Must be taking one the following drugs for at least 21 days before the study: Anastrozole (arimidex), letrozole (femara), or exemestane (aromasin)
4. Must have musculoskeletal symptoms that began after starting one of the drugs above.
5. Other criteria apply
18 - 100
Healthy Volunteers Needed
Duration of Participation
Study drug or placebo will be taken for 13 weeks. Follow-up visits will occur 1 and 11 weeks after the last dose of the study drug or placebo.
Knight Clinical Trials Information Line